Hasil Pencarian  ::  Simpan CSV :: Kembali

"In the last decade, there has been a remarkable explosion of knowledge in hematologic cancer from basic molecular biology and pathology to clinical therapy. This has led to many new advance and insights in the understanding of pathobiology of malignant hematology. New knowledge of disease molecular pathology, cytogenetic, epigenetic and genomic alterations have provided new strategies to attack and eradicate tumor cells at molecular level and significantly impacted our current therapeutics for hematological malignancies. The recent and ongoing rapid expansion of knowledge in this area has become extensive, dynamic and diffuse over the literature and research publications. This has led to the need to capture and compile the new and current information about hematologic cancer with special emphasis on translation from molecular pathobiology to targeted therapeutics. In this book experts from around the world share their thoughts and knowledge about the pathobiology of hematologic cancer, as well as their view on current treatment approaches and future development in these malignant hematologic diseases. "

"The obesity pandemic continues to increase on a world-wide basis with over 70% of the United States population being either overweight or obese. Hematologic malignancies have recently been identified among the obesity associated malignancies spanning the lifespan from childhood to the elderly and include leukemia, myeloma, lymphoma and others. In addition to the etiologic association between obesity and hematologic malignancies, the presence of obesity has profound effects on therapy by impacting pharmacokinetics of chemotherapeutic agents, dose, adipocyte metabolism and drug distribution. These may be particularly important in hematopoietic stem cell transplantation. Another important aspect of the association of obesity with hematologic malignancies is the increased incidence of obesity in children who successfully complete therapy for acute lymphoblastic leukemia. This and other observations indicate important relations between the hematopoietic systems and fat metabolism. This volume on Energy Balance in Hematologic Malignancies will provide an important volume in this series and a basis for better understanding etiology, mechanisms, therapeutics implications and experimental approaches. This volume of energy balance and cancer will focus on the relation of obesity to hematologic malignancies, the epidemiology, potential mechanisms, and thereapeutic considerations including effects on pharmacologic and physical approaches as well as the delayed effects of therapy on energy balance."

"Melanoma is an increasingly important public health problem. Although the cause of most malignant melanomas, over-exposure to ultraviolet light, is well known, effective treatment has remained challenging.The past several years have been marked by extraordinary developments in melanoma treatment in the arena of targeted therapeutics. This book describes these ground-breaking discoveries and their implications for clinical use. As melanoma biology is increasingly understood, so the development of targeted therapies for this disease is spurred ahead. This book covers both established signal transduction inhibitors and the fascinating emerging realm of molecularly-guided immunotherapies.This benchmark book provides the most up-to-date information on the new breed of melanoma therapies. Composed of the works of major researchers and clinicians, this book offers new insights, novel approaches, and promising data for effective treatment planning. "

"The risk of cancer increases with age, and the number of older adults seeking treatment is increasing dramatically in line with the aging population. The care of older patients differs from that of younger adults because of differences in the biology of the tumor, age-related differences in host physiology, comorbidity burden and psychosocial issues, which might impact the efficacy and side effects of cancer therapy. Practical Geriatric Oncology is a comprehensive, evidence-based text that synthesizes the growing literature in this field and provides practical guidelines to the care of older adults with cancer. Coverage includes patient assessment, management of solid tumors and hematologic malignancies, the impact of age on the pharmacology of cancer therapy, surgical oncology and radiation oncology in the older adult, symptom management and supportive care. In addition to serving as core reading for oncologists and hematologists, the book will also be a useful work for other healthcare professionals who provide oncology care, including surgeons, radiation oncologists, palliative care doctors, primary care providers, geriatricians and nurses."

"Latar Belakang. Infeksi jamur invasif (IJI) merupakan salah satu penyebab penting morbiditas dan mortalitas pada pasien dengan keganasan. Penelitian di beberapa negara mengenai kejadian IJI pada anak dengan populasi beragam mendapatkan hasil yang bervariasi, antara 5%-14%. Sampai saat ini belum ditemukan publikasi di Indonesia mengenai prevalens, karakteristik pasien anak dengan leukemia akut yang menderita IJI, spesies jamur penyebab maupun angka kematian akibat IJI. Tujuan. Mengetahui prevalens, manifestasi klinis, spesies jamur penyebab, dan mortalitas infeksi jamur invasif pada anak usia 1 bulan -18 tahun dengan leukemia akut yang mendapat kemoterapi dan mengalami neutropenia. Metode. Penelitian retrospektif deskriptif dengan menggunakan data sekunder dari rekam medis Januari 2010 sampai Desember 2011 dilakukan pada pasien anak dengan leukemia akut yang mendapat kemoterapi dan mengalami neutropenia, dan dirawat di Departemen Ilmu Kesehatan Anak Rumah Sakit Cipto Mangunkusumo (IKA-RSCM). Infeksi jamur invasif ditetapkan berdasarkan kriteria European Organization for Research and Treatment of Cancer (EORTC) 2002. Hasil. Besar sampel diperoleh 218 episode perawatan dari 102 pasien yang memenuhi kriteria inklusi. Prevalens IJI pada perawatan anak dengan leukemia akut dan neutropenia yang mendapat kemoterapi adalah 12 (5,5%) dari 218 perawatan. Kejadian IJI lebih sering pada pasien dengan jenis kelamin laki-laki, usia di atas 6 tahun, leukemia myeloid akut (LMA), dan kemoterapi fase induksi. Faktor pejamu yang paling banyak ditemukan adalah neutropenia>10 hari dengan manifestasi klinis tersering berupa infeksi saluran napas bawah dan lesi kulit. Spesies jamur penyebab IJI yang ditemukan adalah Candida sp. Mortalitas IJI sebesar 8/12 dengan penyebab kematian terbanyak syok sepsis. Kematian yang disebabkan infeksi jamur tidak dilaporkan. Simpulan. Prevalens IJI pada perawatan anak dengan leukemia akut dan neutropenia yang mendapat kemoterapi 5,5%. Spesies jamur penyebab IJI yang ditemukan adalah Candida sp. Tidak semua pasien dengan demam neutropenia dilakukan pemeriksaan biakan jamur. Hal ini dapat mempengaruhi angka kejadian IJI yang sebenarnya sehingga perlu penelitian lebih lanjut yang dilakukan secara prospektif untuk mendapatkan gambaran IJI yang lebih pasti.

---

Background. Invasive fungal infections (IFIs) are a major cause of morbidity and mortality in patients with malignancies. Prevalence of IFIs in children in different countries varies between 5%-14%. There has been no published data of prevalence, characteristics, causative fungi, and mortality rate in children with acute leukemia and chemotherapy-induced neutropenia in Indonesia.

Objectives. To find the prevalence, clinical manifestations, fungal cause, and mortality rate of IFIs in children aged 1 month-18 years with acute leukemia and chemotherapy-induced neutropenia in Indonesia.

Methods. This was a retrospective descriptive study using medical records of children with acute leukemia and chemotherapy-induced neutropenia admitted to Cipto Mangunkusumo Hospital’s Pediatric Department from January 2010-December 2011. Invasive fungal infection was diagnosed according to European Organization for Research and Treatment of Cancer (EORTC) 2002 criteria.

Results. A total of 218 admissions from 102 patients met the inclusion criteria. Prevalence of IFIs in acute leukemia children with chemotherapy-induced neutropenia was 12 (5.5%) from 218 admissions. IFIs were more prevalent in boys, age >6 years old, acute myeloid leukemia (AML), and induction phase of chemotherapy. The most common host factor was neutropenia >10 days, with lower repiratory tract infections and skin lesions as the most common clinical manifestations. Fungal pathogen found was Candida sp. Mortality rate was 8/12 with septic shock as the most common cause of death. IFI related mortality was not reported.

Conclusion. Prevalence of IFIs in children admitted with acute leukemia and chemotherapy-induced neutropenia was 5.5%. Fungal pathogen found was Candida sp. Fungal culture was not done in all patients with febrile neutropenia and this factor could influence the prevalence of IFIs. Further prospective research is needed to find more accurate IFIs characteristics."

"This book provides a state-of-the-art approach to the molecular basis of hematologic diseases and its translation into improved diagnostics and novel therapeutic strategies. Several representative hemato-oncologic malignancies are analyzed in detail: acute lymphoblastic leukemia, acute myeloid leukemia, B-cell Non-Hodgkin lymphomas, multiple myeloma, chronic lymphocytic leukemia, chronic myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms. Experts in the field describe the molecular methods applied for modern diagnostics and therapies, such as hematopoietic stem cell transplantation, donor recipient matching, banking of biological material, analyses of post-transplant chimerism, and minimal residual disease monitoring. The volume concludes with an extensive section comprising thorough step-by-step protocols of molecular techniques in hematology, all of them validated in the authors? own laboratories."

"This new volume in the series focuses on the particular IP issues of therapeutics, vaccines and molecular diagnostics. The first chapter concentrates on basics principles for protecting antibody compounds. Additional ways to create follow-up protection for antibody therapeutics are also discussed. The second chapter gives an overview of the patent landscape in molecular diagnostics, and discusses issues of patentability with respect to the different technologies and compounds used therein. The third chapter gives a broad overview of areas of law that are particularly relevant to the patenting of peptide vaccines and therapeutic peptides as products and in compositions. The scope of patentable subject matter is discussed, as it has been the focus of much wrangling and debate in the courts."

"Explains when and how you can use them to most effectively combat cancer. This concise, practical oncology reference examines more than 120 targeted therapy agents for which clinical trial data are available."